文献速递食管胃疾病与幽门螺杆菌

原发性抗生素耐药对幽门螺杆菌序贯疗法疗效的影响:基于大量菌株的5年研究启示

Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains.
PubMed 文献 · Aliment Pharmacol Ther · 2018-03-14

研究纳入2010至2015年1682例初治幽门螺杆菌阳性患者,用E-test评估克拉霉素、甲硝唑和左氧氟沙星的原发性耐药。序贯疗法对克拉霉素和甲硝唑均敏感菌株的根除率为97.3%,对双耐药菌株为83.1%。原发性耐药率上升且是影响疗效的最关键因素。

要点

  • 序贯疗法对克拉霉素和甲硝唑双敏感菌株根除率97.3%(95%CI 95.6-98.4)。
  • 对克拉霉素和甲硝唑双耐药菌株根除率83.1%(95%CI 77.7-87.3)。
  • 评估耐药菌株根除疗效需研究约98-144例耐药菌株患者。

核心结论

  • 幽门螺杆菌原发性耐药率上升,是影响疗效的最关键因素。
  • 序贯疗法对克拉霉素和甲硝唑双耐药菌株的根除率为83%。
  • 只有评估大量菌株才能可靠估计某方案在耐药菌株患者中的疗效。

研究设计与样本

  • 研究纳入2010至2015年间连续1682例初治幽门螺杆菌阳性接受上消化道内镜检查的患者。
  • 采用E-test评估菌株对克拉霉素、甲硝唑和左氧氟沙星的原发性耐药。
  • 提供序贯疗法并评估其根除疗效。

主要发现

  • 测试的抗菌药物原发性耐药率高,且2010至2015年间上升。
  • 对克拉霉素和甲硝唑均敏感菌株的根除率为97.3%(95%CI 95.6-98.4)。
  • 对甲硝唑耐药但克拉霉素敏感菌株的根除率为96.1%(95%CI 91.7-98.2)。
  • 对克拉霉素耐药但甲硝唑敏感菌株的根除率为93.4%(95%CI 88.2-96.4)。
  • 对克拉霉素和甲硝唑均耐药菌株的根除率为83.1%(95%CI 77.7-87.3)。

关键数值与推荐

  • 对于根除率在75%-85%的方案,需研究约98-144例耐药菌株患者才能获得可靠的疗效信息。
  • 原发性耐药评估采用E-test法。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing prevalence of strains resistant to antimicrobial agents is a critical issue in the management of Helicobacter pylori (H. pylori) infection. AIMS: (1) To evaluate the prevalence of primary resistance to clarithromycin, metronidazole and levofloxacin (2) to assess the effectiveness of sequential therapy on resistant strains (3) to identify the minimum number of subjects to enrol for evaluating the effectiveness of an eradication regimen in patients harbouring resistant strains. METHODS: Consecutive 1682 treatment naïve H. pylori-positive patients referred for upper GI endoscopy between 2010 and 2015 were studied and resistances assessed by E-test. Sequential therapy was offered, effectiveness evaluated and analysed. RESULTS: H. pylori-primary resistance to antimicrobials tested was high, and increased between 2010 and 2015. Eradication rates were (estimates and 95% CIs): 97.3% (95.6-98.4) in strains susceptible to clarithromycin and metronidazole; 96.1% (91.7-98.2) in strains resistant to metronidazole but susceptible to clarithromycin; 93.4% (88.2-96.4) in strains resistant to clarithromycin but susceptible to metronidazole; 83.1% (77.7-87.3) in strains resistant to clarithromycin and metronidazole. For any treatment with a 75%-85% eradication rate, some 98-144 patients with resistant strains need to be studied to get reliable information on effectiveness in these patients. CONCLUSIONS: H. pylori-primary resistance is increasing and represents the most critical factor affecting effectiveness. Sequential therapy eradicated 83% of strains resistant to clarithromycin and metronidazole. Reliable estimates of the effectiveness of a given regimen in patients harbouring resistant strains can be obtained only by assessing a large number of strains.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gatta L, Scarpignato C, Fiorini G, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther. 2018. PMID: 29536561. doi:10.1111/apt.14597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。